V-safe: Summary of findings reported after COVID-19 vaccination to a US CDC active safety surveillance system through June 2023
Vaccine·
- DOI
- 10.1016/j.vaccine.2026.128725
- PMID
- 42378925
- PMCID
- —
- OpenAlex
- W7166533270
- Study type
- Journal article
- Publisher
- Elsevier BV
- Article type
- journal-article
- Integrity
- current
Why this research matters now
Continuous tracking of self-reported tolerability complements traditional clinical trial metrics and supports ongoing evaluation of emerging immunization products. Identifying engagement drop-offs informs strategy development for sustaining participant involvement during future public health emergencies.
Structured evidence summary
Research question
What demographic profiles, enrollment trajectories, and self-reported health outcomes characterize recipients of COVID-19 immunizations monitored through a national active tracking network?
Study design
A descriptive observational analysis leveraging a voluntary, text-delivered surveillance platform that administered scheduled health assessments at fixed intervals following immunization.
Population and setting
Approximately 9.6 million US individuals who participated in the monitoring program between late 2020 and mid-2023, predominantly females aged twenty-five to sixty-four who received messenger RNA formulations.
Main findings
Survey engagement peaked shortly after vaccination guidelines expanded, then steadily declined across subsequent doses and among younger age groups. Symptom reporting concentrated within the initial seven days post-administration, demonstrated higher frequency following the second injection compared to the first, and varied by manufacturer. Routine medical consultations remained uncommon, affecting roughly one percent of adults during the early observation window.
Public-health relevance
Continuous tracking of self-reported tolerability complements traditional clinical trial metrics and supports ongoing evaluation of emerging immunization products. Identifying engagement drop-offs informs strategy development for sustaining participant involvement during future public health emergencies.
Important limitations
Voluntary enrollment produced a cohort that diverged from the broader vaccinated demographic distribution. Natural disengagement over extended follow-up periods and across repeated administrations may reduce longitudinal data completeness. Outcomes depend entirely on participant self-assessment without independent clinical verification.
GIDS interpretation
The publication documents the operational scope and historical output of a federal monitoring initiative, offering structural context for how large-scale immunization tracking networks function. It establishes a baseline for understanding temporal enrollment dynamics and reporting patterns within established public health infrastructure.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 13 auditable classifier relationships to diseases, places, topics, and study design.